文献速递内脏/肾动脉与血管畸形

慢性肠系膜缺血的生存、再干预及开放与腔内修复的价值

Survival, Reintervention, and Value of Open and Endovascular Repair for Chronic Mesenteric Ischemia.
PubMed 文献 · Ann Vasc Surg · 2023-09-01

基于纽约州全支付方数据库2000至2014年744例慢性肠系膜缺血患者的回顾性队列分析,209例(28.1%)接受开放修复,535例(71.9%)接受腔内修复。倾向性匹配后两组1年(P=0.46)和5年(P=0.91)生存无差异,长期死亡与患者合并症相关;腔内修复5年再干预增加(P<0.01)且5年价值更高。

要点

  • 倾向性匹配后开放修复与腔内修复的1年(P=0.46)和5年(P=0.91)生存无差异。
  • 长期死亡与合并症相关,而非治疗方式。
  • 腔内修复5年再干预增加(P<0.01),但5年价值更高。

核心结论

  • 长期死亡与治疗方式无关,而与患者合并症相关;治疗选择应取决于解剖因素和长期价值。
  • 对于解剖适合的患者,基于更优的干预价值,应考虑腔内修复而非开放修复。

研究设计与样本

  • 回顾性队列分析,数据来自纽约州全支付方数据库(Statewide Planning and Research Cooperative System),纳入2000至2014年744例慢性肠系膜缺血患者,其中209例(28.1%)接受开放修复,535例(71.9%)接受腔内修复,并采用倾向性匹配队列比较。

主要发现

  • 倾向性匹配组间1年生存无差异(P=0.46),5年生存无差异(P=0.91)。
  • 充血性心力衰竭(HR 2.8,95%CI 1.7-4.4;P<0.01)、癌症(HR 2.8,95%CI 1.3-5.8;P<0.01)和心律失常(HR 1.8,95%CI 1.1-2.8;P=0.02)与1年死亡相关。
  • 癌症(HR 2.9,95%CI 1.6-5.5;P<0.01)、充血性心力衰竭(HR 2.2,95%CI 1.5-3.2;P<0.01)、慢性肺病(HR 1.4,95%CI 1.0-2.0;P=0.04)和年龄(HR 1.03,95%CI 1.01-1.05;P<0.01)与5年死亡相关。
  • Kaplan-Meier分析显示治疗方式与1年再干预无关(P=0.29),但腔内修复5年再干预增加(P<0.01)。
  • 腔内修复与5年价值增加相关(0.7±0.9 vs 0.5±0.5生命年/指数住院费用[$10k],P<0.01;b系数0.2,95%CI 0.1-0.4,P<0.01)。

关键数值与推荐

  • 当前指南推荐对较年轻、较健康且长期获益超过增加围手术期风险的患者,或对腔内修复候选条件差的患者,行开放修复。

临床怎么用

  • 作者认为,治疗选择应取决于解剖因素和长期价值。
  • 作者认为,对于解剖适合的患者,基于更优的干预价值,应考虑腔内修复而非开放修复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited analyses of survival and postoperative outcomes in chronic mesenteric ischemia (CMI) using data from large cohorts. Current guidelines recommend open repair (OR) for younger, healthier patients when long-term benefits outweigh increased perioperative risks or for poor endovascular repair (ER) candidates. This study investigates whether long-term survival, reintervention, and value differ between these treatment modalities. METHODS: A retrospective cohort analysis was performed on data extracted from the Statewide Planning and Research Cooperative System, the New York statewide all-payer database containing demographics, diagnoses, treatments, and charges. Patients were selected for CMI and subsequent ER or OR using International Classification of Diseases, Ninth Revision codes. Patients with peripheral arterial disease were excluded to account for ambiguity in the International Classification of Diseases, Ninth Revision procedure code for angioplasty of noncoronary vessels, which includes angioplasty of upper and lower extremity vessels. Kaplan-Meier analysis was used to compare 1-year and 5-year survival and reintervention between treatment modalities using a propensity-matched cohort. Cox proportional hazards testing was performed to find factors associated with 1-year and 5-year survival and reintervention. Analysis of procedural value was performed using linear regression. RESULTS: From 2000 to 2014, 744 patients met inclusion criteria. Of these, 209 (28.1%) underwent OR and 535 (71.9%) ER. No difference between propensity-matched groups was found in 1-year (P = 0.46) or 5-year (P = 0.91) survival. Congestive heart failure (hazard ratio [HR]: 2.8, 95% confidence interval [CI]: 1.7-4.4; P < 0.01), cancer (HR: 2.8, 95% CI: 1.3-5.8; P < 0.01), and dysrhythmia (HR: 1.8, 95% CI: 1.1-2.8; P = 0.02) correlated with 1-year mortality. Cancer (HR: 2.9, 95% CI: 1.6-5.5; P < 0.01), congestive heart failure (HR: 2.2, 95% CI: 1.5-3.2; P < 0.01), chronic pulmonary disease (HR: 1.4, 95% CI: 1.0-2.0; P = 0.04), and age (HR: 1.03, 95% CI: 1.01-1.05; P < 0.01) correlated with 5-year mortality. Treatment modality was not associated with reintervention at 1 year on Kaplan-Meier analysis (P = 0.29). However, ER showed increased instances of reintervention at 5 years (P < 0.01). Additionally, ER was associated with an increased 5-year value (0.7 ± 0.9 vs. 0.5 ± 0.5 life years/charges at index admission [$10k], P < 0.01; b coefficient: 0.2, 95% CI: 0.1-0.4, P < 0.01). CONCLUSIONS: This is the largest retrospective propensity-matched single-study cohort to analyze long-term survival outcomes after intervention for CMI. Long-term mortality was independent of treatment modality and rather was associated with patient comorbidities. Therefore, treatment selection should depend on anatomic considerations and long-term value. ER should be considered over OR in patients with amenable anatomy based on the superior procedural value.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lehane DJ, Geiger JT, Zottola ZR, et al. Survival, Reintervention, and Value of Open and Endovascular Repair for Chronic Mesenteric Ischemia. Ann Vasc Surg. 2023. PMID: 37659648. doi:10.1016/j.avsg.2023.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。